Wellington Management Group LLP decreased its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 50.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 504,687 shares of the company's stock after selling 523,551 shares during the quarter. Wellington Management Group LLP owned approximately 1.20% of SI-BONE worth $7,076,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in SIBN. FMR LLC increased its position in SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after buying an additional 1,198 shares during the period. Rhumbline Advisers raised its holdings in SI-BONE by 3.0% during the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock worth $808,000 after purchasing an additional 1,683 shares in the last quarter. Franklin Resources Inc. lifted its position in SI-BONE by 9.4% in the third quarter. Franklin Resources Inc. now owns 20,220 shares of the company's stock valued at $265,000 after purchasing an additional 1,745 shares during the period. Mainstream Capital Management LLC purchased a new stake in SI-BONE in the 4th quarter valued at approximately $53,000. Finally, R Squared Ltd acquired a new position in SI-BONE during the 4th quarter worth approximately $73,000. Institutional investors and hedge funds own 98.11% of the company's stock.
Insider Buying and Selling
In related news, insider Anthony J. Recupero sold 3,311 shares of SI-BONE stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total value of $46,850.65. Following the transaction, the insider now owns 284,555 shares of the company's stock, valued at approximately $4,026,453.25. This trade represents a 1.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the business's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the sale, the senior vice president now owns 244,878 shares in the company, valued at approximately $3,462,574.92. The trade was a 1.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,776 shares of company stock valued at $96,644 over the last three months. Company insiders own 3.90% of the company's stock.
SI-BONE Price Performance
SIBN traded up $0.15 on Wednesday, reaching $13.20. The company had a trading volume of 61,744 shares, compared to its average volume of 361,961. The company has a market capitalization of $560.34 million, a P/E ratio of -14.34 and a beta of 1.02. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The company has a fifty day moving average of $15.47 and a 200-day moving average of $14.63. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $19.16.
SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05. The business had revenue of $49.00 million for the quarter, compared to analyst estimates of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. As a group, equities research analysts anticipate that SI-BONE, Inc. will post -0.78 earnings per share for the current year.
Analyst Ratings Changes
SIBN has been the topic of several research analyst reports. Truist Financial reissued a "buy" rating and set a $22.00 price target (up previously from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Needham & Company LLC increased their price target on shares of SI-BONE from $20.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $24.40.
Check Out Our Latest Report on SI-BONE
SI-BONE Profile
(
Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Featured Stories
Before you consider SI-BONE, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SI-BONE wasn't on the list.
While SI-BONE currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
